Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106
22/06/2026 02:22
BRIEF-Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106 June 22 (Reuters) - Antengene Corp Ltd 6996.HK:
ENTERS EXCLUSIVE LICENSE AGREEMENT WITH K2 THERAPEUTICS FOR ATG-106
TO RECEIVE ABOUT $20 MILLION UPFRONT AND NEAR-TERM CONSIDERATION
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106